

# CHU-SARI study: Role of respiratory viruses in adult hospitalizations for severe acute respiratory infections (SARI)

|  |  |  |
|--|--|--|
| <b>Submission date</b><br>20/01/2014   | <b>Recruitment status</b><br>No longer recruiting        | <input type="checkbox"/> Prospectively registered<br><input type="checkbox"/> Protocol                       |
| <b>Registration date</b><br>21/02/2014 | <b>Overall study status</b><br>Completed                 | <input type="checkbox"/> Statistical analysis plan<br><input type="checkbox"/> Results                       |
| <b>Last Edited</b><br>27/02/2014       | <b>Condition category</b><br>Infections and Infestations | <input type="checkbox"/> Individual participant data<br><input type="checkbox"/> Record updated in last year |

## Plain English summary of protocol

### Background and study aims

Winter hospitalizations for severe acute respiratory infections (SARI) due to an influenza virus have been assessed at University Hospital CHU Mont-Godinne since the 2009 influenza A/H1N1 pandemic wave. All patients presenting to the Emergency Department (ED) are screened according to a SARI case definition. Nasopharyngeal swabs are collected to test for influenza. Recent studies have focused on the role of other respiratory viruses as a cause of illness and death during the winter months. The aims of the study are to assess the impact of influenza and other respiratory viruses during the 2013-2014 winter season, along with the use of internal diagnostic methods in virology.

### Who can participate ?

Adult patients matching with the SARI case definition (fever > 38°C or history of fever associated with cough and/or dyspnea (shortness of breath), and requiring hospitalization for more than 24 h), who consent for nasopharyngeal swabbing.

### What does the study involve ?

SARI patients will be screened at admission. Nasopharyngeal swabbing is considered as routine practice for SARI patients hospitalized at CHU Mont-Godinne. Infection control measures (transmission-based precautions) are applied as recommended for suspected or documented respiratory viral pathogens. Medical management of patients follows recommendations regarding antiviral treatment for influenza infection, and eventual antibiotic therapy adaptation.

### What are the possible benefits and risks of participating ?

The benefits for the patients are the possible initiation of an antiviral treatment for documented influenza infection, and the possible adaptation of antibiotic therapy in case of viral documented infection (influenza and/or another respiratory virus). There are no risks for patients included in the study, as nasopharyngeal swabbing is a non-invasive procedure, and all the medical interventions carried out are same as that performed in standard practice.

Where is the study run from ?  
University Hospital Mont-Godinne at Yvoir (Belgium).

When is the study starting and how long is it expected to run for ?  
Recruitment started in November 2013 and study will run until April 2014. Participants will be enrolled on the study up to the end of winter period, 2014.

Who is funding the study ?  
Mont-Godinne Foundation, Belgium.

Who is the main contact ?  
Professor Bénédicte Delaere  
Mr Marc Bourgeois, marc.bourgeois@uclouvain.be

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Bénédicte Delaere

**Contact details**  
CHU Mont-Godinne (Catholic University of Louvain)  
Infectious Diseases Unit  
Av Dr G Therasse 1  
Yvoir  
Belgium  
5530

## Additional identifiers

**Protocol serial number**  
N/A

## Study information

**Scientific Title**  
A descriptive observational cohort study to determine the role of respiratory viruses in adult hospitalizations for severe acute respiratory infections (SARI)

**Acronym**  
CHU-SARI

**Study objectives**  
It is hypothesized that winter hospitalizations for acute respiratory infections related to viral pathogens are underestimated. Influenza can lead to severe acute infection, but other respiratory viruses may also contribute to morbidity and mortality, especially in adult patients with risk factors.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

CHU Mont-Godinne Ethics Committee, 14/11/2013, ref. BUN 039201318786

**Study design**

Descriptive observational cohort study

**Primary study design**

Observational

**Study type(s)**

Screening

**Health condition(s) or problem(s) studied**

Infectious diseases/Respiratory viruses/Epidemiology

**Interventions**

Screening of SARI patients at admission

Nasopharyngeal swabbing

Multiplex rt-PCR for respiratory viruses

Collection and analysis of clinical and epidemiological data

**Intervention Type**

Other

**Phase**

Not Applicable

**Primary outcome(s)**

1. Patients positive for at least one respiratory virus
2. Patients with risk factors

All outcomes measured by prospective and retrospective review of electronic medical charts of enrolled patients (date of admission as baseline, date of discharge, and date of medical hospitalization report completed).

**Key secondary outcome(s)**

1. Viral co-infections with two or more respiratory viruses
2. Bacterial co-infections
3. Epidemiology, clinical course and outcome (risk factors, length of stay, complications, intensive care admission, death)
4. Instauration of antiviral treatment following virological diagnosis
5. Adaptation of antibiotic treatment following virological diagnosis

**Completion date**

15/04/2014

**Eligibility**

**Key inclusion criteria**

1. Adult (aged above 16 years)
2. New admission and within 7 days of admission
3. Fever > 38 or history of fever, cough and/or dyspnea
4. Requiring hospitalization for over 24h
5. Oral consent for nasopharyngeal swabbing

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Patients under 16 years of age
2. Patients already hospitalized and developing a SARI

**Date of first enrolment**

15/11/2013

**Date of final enrolment**

15/04/2014

**Locations****Countries of recruitment**

Belgium

**Study participating centre**

CHU Mont-Godinne (Catholic University of Louvain)

Yvoir

Belgium

5530

**Sponsor information****Organisation**

Mont-Godinne Foundation (Belgium)

# Funder(s)

## Funder type

Charity

## Funder Name

Mont-Godinne Foundation (Belgium) (CHU Mont-Godinne, Catholic University of Louvain)  
(Belgium)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

| Output type                                   | Details                       | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|-------------------------------|--------------|------------|----------------|-----------------|
| <a href="#">Participant information sheet</a> | Participant information sheet | 11/11/2025   | 11/11/2025 | No             | Yes             |